DiaMedica Therapeutics Inc.

Diamedica Therapeutics Inc.

Biotechnology • Healthcare • Minneapolis, MN, United States • DMAC (NCM)

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company also develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

763 496 5454 301 Carlson Parkway, Minneapolis, MN 55305, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade - Yahoo Finance
Yahoo Finance • Sep 8
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA - Business Wire
Business Wire • Dec 18
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
MarketBeat • Dec 19
After-Hours Biotech Rally: Inspira, MediciNova, DiaMedica Therapeutics Among Gainers - Nasdaq
Nasdaq • Dec 19
DiaMedica Therapeutics (Nasdaq: DMAC) to release Q3 results after close; call Nov. 13 - Stock Titan
Stock Titan • Nov 6

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has DiaMedica Therapeutics Inc. had layoffs?
No layoff events have been recorded for DiaMedica Therapeutics Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does DiaMedica Therapeutics Inc. have?
DiaMedica Therapeutics Inc. has approximately 27 employees.
What industry is DiaMedica Therapeutics Inc. in?
DiaMedica Therapeutics Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is DiaMedica Therapeutics Inc. a publicly traded company?
Yes, DiaMedica Therapeutics Inc. is publicly traded under the ticker symbol DMAC on the NCM. The company has a market capitalization of approximately $0.43 billion.
Where is DiaMedica Therapeutics Inc. headquartered?
DiaMedica Therapeutics Inc. is headquartered in Minneapolis, MN, United States at 301 Carlson Parkway, Minneapolis, MN 55305, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.